WikiJournalClub:List of landmark papers/Rheumatology

Rheumatoid Arthritis

Methotrexate a/w lower mortality [[1]]
BeSt: Comparison of Treatment Strategies: DMARD vs. DMARD/prednisone vs. DMARD/infliximab in early RA [[2]][[3]]
Abatacept in patients who had had an inadequate response to anti–TNF-α therapy. [[4]]
Rituximab [[5]]
Certolizumab [[6]]
OPTION tocilizumab [[7]]
COMET methotrexate monotherapy versus combination of methotrexate and etanercept [[8]]
GO-AFTER Golimumab [[9]]
BARFOT Prednisolone + DMARD retarded the progression of radiographic damage in patients with early RA, provided a high remission rate, and was well tolerated. [[10]]
Low dose prednisolone + DMARD [[11]]

Higher levels of meat and seafood consumption are associated with an increased risk of gout, whereas a higher level of consumption of dairy products is associated with a decreased risk. Moderate intake of purine-rich vegetables or protein is not associated with an increased risk of gout. [[13]]
Alcohol increases risk of gout [[14]]
Oral prednisolone versus naproxen [[15]]
Colchicine reduces acute flares [[16]]
Febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function. [[17]][[18]]
CONFIRMS Febuxostat high dose versus febuxostat low dose versus allopurinol [[19]]

Scleroderma Lung Study Cyclophosphamide in pts with symptomatic scleroderma-related ILD [[21]]

Fishoil improves tolerance to cold exposure and delays the onset of vasospasm in patients with primary, but not secondary, Raynaud's phenomenon. [[22]]

Autoantibodies in SLE [[23]]
For patients with proliferative lupus nephritis, short-term therapy with intravenous cyclophosphamide followed by maintenance therapy with mycophenolate mofetil or azathioprine appears to be more efficacious and safer than long-term therapy with intravenous cyclophosphamide. [[24]]
mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile. [[25]]
ALMS Mycophenolate vs. azathioprine as maintenance therapy for lupus nephritis [[26]]
RAVE-ITN Rituximab vs. cyclophosphamide for ANCA-associated vasculitis [[27]]
EVS Rituximab vs. cyclophosphamide in ANCA-associated renal vasculitis [[28]]
LUNAR Rituximab in patients with lupus nephritis Arthritis Rheum 2012 Jan 9 PMID: 22231479

Bilateral temporal artery biopsy increases yield [29]
In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse. Thus, the duration of exposure to cyclophosphamide may be safely reduced. [30]
The pulse cyclophosphamide regimen induced remission of ANCA-associated vasculitis as well as the daily oral regimen at a reduced cumulative cyclophosphamide dose and caused fewer cases of leukopenia. [31]
ANCA levels cannot be used to guide immunosuppressive therapy. [32]
RITUXVAS - Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis [33]
RAVE - Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis [34]
NORAM - Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis [35]